Replies to post #5661 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>We need to see what kind of a deal GTCB can make for profits in the US market.<

The US partnership deal will presumably have better economics for GTC than the ex-US/ex-Japan ATryn deal with Leo—the question is how much better. Ditto for the Japanese ATryn partnership. Regards, Dew